Stephens Inc. AR Sells 746 Shares of Boston Scientific Corporation (NYSE:BSX)

Stephens Inc. AR decreased its holdings in Boston Scientific Corporation (NYSE:BSX) by 7.1% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,800 shares of the medical equipment provider’s stock after selling 746 shares during the quarter. Stephens Inc. AR’s holdings in Boston Scientific were worth $989,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in BSX. Brighton Jones LLC boosted its stake in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares during the last quarter. Bank Pictet & Cie Europe AG boosted its position in shares of Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider’s stock valued at $6,529,000 after acquiring an additional 21,173 shares during the period. Highview Capital Management LLC DE raised its stake in Boston Scientific by 6.2% in the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider’s stock valued at $2,189,000 after purchasing an additional 1,439 shares in the last quarter. Proficio Capital Partners LLC increased its stake in shares of Boston Scientific by 40.2% in the fourth quarter. Proficio Capital Partners LLC now owns 5,333 shares of the medical equipment provider’s stock worth $476,000 after buying an additional 1,528 shares during the period. Finally, Madison Investment Advisors LLC purchased a new position in Boston Scientific during the 4th quarter valued at $263,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Up 1.4%

Boston Scientific stock opened at $104.62 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.88 and a current ratio of 1.45. The firm has a market capitalization of $154.78 billion, a price-to-earnings ratio of 76.37, a price-to-earnings-growth ratio of 2.68 and a beta of 0.68. The stock’s fifty day moving average is $103.40 and its two-hundred day moving average is $100.90. Boston Scientific Corporation has a fifty-two week low of $71.88 and a fifty-two week high of $107.53.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.08. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The business had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same period in the previous year, the company posted $0.56 EPS. The company’s revenue was up 20.9% compared to the same quarter last year. Analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on BSX. Morgan Stanley upped their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the company an “overweight” rating in a research note on Friday, May 16th. Robert W. Baird lifted their target price on Boston Scientific from $115.00 to $120.00 and gave the stock an “outperform” rating in a research report on Thursday, April 24th. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, April 29th. Needham & Company LLC reiterated a “buy” rating and issued a $115.00 target price on shares of Boston Scientific in a research report on Wednesday, May 28th. Finally, Royal Bank Of Canada increased their target price on Boston Scientific from $116.00 to $120.00 and gave the company an “outperform” rating in a research report on Thursday, April 24th. Twenty-two equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $116.09.

Insiders Place Their Bets

In other Boston Scientific news, SVP Vance R. Brown sold 4,826 shares of the business’s stock in a transaction on Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the transaction, the senior vice president owned 36,193 shares in the company, valued at approximately $3,441,592.37. The trade was a 11.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $106.97, for a total value of $5,348,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $19,077,243.74. This trade represents a 21.90% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 461,970 shares of company stock worth $47,755,193. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.